Compared to matched normal tissue, SNHG3 is upregulated in tumor tissues, such as osteosarcoma [19, 36], glioma [20], ovarian cancer [21], breast cancer [22, 34], hepatocellular carcinoma [23, 24, 35], acute myeloid leukemia [29], non-small-cell lung cancer [30], papillary thyroid carcinoma [31], intrahepatic cholangiocarcinoma [32], and gastric cancer [33], and usually brings poor clinical outcomes, including OS, DFS, RFS, stage, grade, tumor size, distant metastasis, and lymph node metastasis. The gene discussed is SNHG3; the disease is glioma.